Clinical activity and validation of the disability disc in inflammatory bowel disease
Main Article Content
Keywords
Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease, Disability Evaluation, IBD-Disk
Abstract
Abstract
Background: Inflammatory bowel disease (IBD) is a chronic immune-mediated pathology that causes disability and can be assessed by the simplified IBD-Disk tool, which could be conditioned by clinical activity.
Objective: Associate disability with clinical activity using the IBD-DISK tool validated in patients with IBD.
Methods: Analytical cross-sectional study in 101 outpatients and inpatients diagnosed with IBD. After obtaining informed consent, the IBD-Disk tool for disability was validated and administered, as well as its correlation with the IBD-DI. Clinical activity was assessed with the Mayo score for chronic nonspecific ulcerative colitis (CUCI) and the Harvey-Bradshaw score for Crohn's disease (CD). The association between disability and clinical activity was performed with a regression model.
Results: The reliability of the IBD-Disk was > 0.900. Patients with CUCI and moderate or severe clinical activity are 8.2 times more likely to have an IBD-Disk score > 40 compared to those in remission or with mild activity. Patients with Crohn´s disease the association was OR = 2.4 (95%CI: 0.19 - 31.52). The regression model shows that clinical activity (Mayo and Harvey-Bradshaw) is the factor that most influences the disability scales (B = 4.400).
Conclusions: IBD-Disk is a reliable instrument for measuring disability in CUCI and CD. Although disability does not differ significantly between CUCI and CD, clinical activity is associated with disability (IBD-Disk).
References
1. Prokopič M, Gilca-Blanariux G, Lietava P, et al. Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis. Therap Adv Gastroenterol. 2023;16:17562848231174290. doi: 10.1177/17562848231174290
2. Yamamoto-Furusho JK, Bosques-Padilla FJ, Charúa-Guindic L, et al. Inflammatory bowel disease in Mexico: Epidemiology, burden of disease, and treatment trends. Epidemiología, carga de la enfermedad y tendencias de tratamiento de la enfermedad inflamatoria intestinal en México. Rev Gastroenterol Mex (Engl Ed). 2020;85(3):246-256. doi: 10.1016/j.rgmx.2019.07.008
3. Okobi OE, Udoete IO, Fasehun OO, et al. A Review of Four Practice Guidelines of Inflammatory Bowel Disease. Cureus. 2021;13(8):e16859. doi: 10.7759/cureus.16859
4. Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402(10401):571-584. doi: 10.1016/S0140-6736(23)00966-2.
5. Singh S, Loftus EV Jr, Limketkai BN, et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2024;167(7):1307-1343. doi: 10.1053/j.gastro.2024.10.001
6. Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. doi: 10.1038/s41572-020-0205-x
7. Le Berre C, Flamant M, Bouguen G, et al. VALIDation of the IBD-Disk Instrument for Assessing Disability in Inflammatory Bowel Diseases in a French Cohort: The VALIDate Study. J Crohns Colitis. 2020;14(11):1512-1523. doi: 10.1093/ecco-jcc/jjaa100
8. Ghosh S, Louis E, Beaugerie L, et al. Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2017;23(3):333-340. doi: 10.1097/MIB.0000000000001033
9. Tadbiri S, Nachury M, Bouhnik Y, et al. The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. J Crohns Colitis. 2021;15(5):766-773. doi: 10.1093/ecco-jcc/jjaa244
10. Naftali T, Richter V, Mari A, et al. The inflammatory bowel disease disk application: A platform to assess patients' priorities and expectations from treatment. J Dig Dis. 2021;22(10):582-589. doi: 10.1111/1751-2980.13045
11. Tannoury J, Nachury M, Martins C, et al. Determinants of IBD-related disability: a cross-sectional survey from the GETAID. Aliment Pharmacol Ther. 2021;53(10):1098-1107. doi: 10.1111/apt.16353
12. Meeralam Y, Al-Zanbagi AB, Al Saedi M, et al. IBD-Disk as a tool estimating the prevalence of inflammatory bowel disease-related disability and associated influencing factors in Saudi Arabia: A cross-sectional study. Saudi J Gastroenterol. 2023;29(5):309-315. doi: 10.4103/sjg.sjg_3_23
13. Nigro CMC, Ferreira SDC, Machado VF, et al. Translation, cross-cultural adaptation, and validation of the ibd disk for use in patients with inflammatory bowel diseases in the brazilian population. Arq Gastroenterol. 2024;61:e23058. doi: 10.1590/S0004-2803.24612024-058
14. Hilton A and Skrutkowski M. Translating instruments into other languages: development and testing processes. Cancer Nurs 2002; 25: 1-7. doi: 10.1097/00002820-200202000-00001.
15. Calviño-Suárez C, Ferreiro-Iglesias R, Bastón-Rey I, et al. Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment. Int J Environ Res Public Health. 2021;18(13):7159. doi: 10.3390/ijerph18137159.
16. Nardone OM, Bruzzese D, Allocca M, et al. Italian validation of the IBD-disk tool for the assessment of disability in inflammatory bowel diseases: A cross-sectional multicenter study. Dig Liver Dis. 2025;57(3):753-761. doi: 10.1016/j.dld.2024.11.004
17. López-Cortés R, Herrero-Hahn R, De la Rosa-Eduardo R, et al. Cultural Adaptation and Validation of the Inflammatory Bowel Disease Disability Index in a Spanish Population and Its Association with Sociodemographic and Clinical Factors. Int J Environ Res Public Health. 2019;16(4):635.
18. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031
19. Fumery M, Altwegg R, Aygalenq P, et al. Disease burden of patients with moderate to severe ulcerative colitis: A French multicenter real-life study (THEFAR). Dig Liver Dis. 2025;57(1):251-259. doi: 10.1016/j.dld.2024.08.044
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.